clinical trial · NCT06100900
Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Paroxysmal Nocturnal HemoglobinuriaBCX10013
brief summary
This is a multicenter, open-label, intra-subject, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and therapeutic potential of BCX10013 in participants with PNH. Approximately 8 participants will be enrolled in this study. Participants may receive treatment for up to 52 weeks.
started
Oct 24, 2023
primary completion
Dec 11, 2024
completion
Dec 11, 2024
last updated
Jan 8, 2025
official title
An Open-Label, Multicenter, Intra-Subject Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Therapeutic Potential of BCX10013 in Subjects with Paroxysmal Nocturnal Hemoglobinuria
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol